Novel Approach to Treat Cognitive Symptoms of Schizophrenia
Phrenix Therapeutics (Spinout) - Small molecule for Schiziophrenia
Tags: Monash University, Australia, Healthcare & Lifesciences
Phrenix, emerging from Monash University, introduces a novel class of agonists for treating schizophrenia by targeting positive, negative, and cognitive symptoms with reduced side effects. This biased agonist approach utilizes advanced neuronal signaling insights and pathway fingerprinting for developing anti-psychotic and procognitive agents. Unlike current treatments, which often impair cognitive function, Phrenix's technology promises enhanced efficacy. The technology fills a gap in treating schizophrenia's cognitive symptoms, offering a groundbreaking solution for comprehensive symptom management.
IP Type or Form Factor: Patent Pending; Process & Method; Platform
TRL: Not specified
Industry or Tech Area: Mental Health; Biotechnology
![Phrenix Therapeutics (Spinout) - Small molecule for Schiziophrenia](https://substackcdn.com/image/fetch/w_720,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F632fca7c-f780-4dbf-b8a7-2e9b492a8b55_1024x1024.jpeg)
![Phrenix Therapeutics (Spinout) - Small molecule for Schiziophrenia](https://substackcdn.com/image/fetch/w_720,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F547b71b3-c77d-4017-875f-bd211681a462_342x342.jpeg)